Biomarkers will be developed to advance Pfizer’s cancer and inflammation pipelines with the potential to jointly commercialize companion diagnostics.



Source MDx and Pfizer entered into a multiyear collaboration to develop biomarkers within Pfizer’s cancer and inflammation development programs. Additionally, validation of candidate biomarkers will lead to joint commercial opportunities in companion diagnostics.


This molecular diagnostics partnership will combine Pfizer’s experience in genomic profiling with Source MDx’ expertise in RNA transcription profiling. The companies will work together on clinical studies to identify RNA-based pharmacodynamic and predictive biomarkers in whole blood and circulating rare cells. The goal is to establish molecular profiles of response and resistance for cancer and inflammation drugs.


Source MDx will receive an equity investment and a technology license fee plus R&D funding over the term of the alliance. The firm will retain commercial rights to diagnostic biomarkers discovered through this agreement. Pfizer and Source MDx may commercialize any companion diagnostics that are developed as part of the collaboration.








This site uses Akismet to reduce spam. Learn how your comment data is processed.